104,95 €
104,95 €
inkl. MwSt.
Sofort per Download lieferbar
payback
52 °P sammeln
104,95 €
104,95 €
inkl. MwSt.
Sofort per Download lieferbar

Alle Infos zum eBook verschenken
payback
52 °P sammeln
Als Download kaufen
104,95 €
inkl. MwSt.
Sofort per Download lieferbar
payback
52 °P sammeln
Jetzt verschenken
104,95 €
inkl. MwSt.
Sofort per Download lieferbar

Alle Infos zum eBook verschenken
payback
52 °P sammeln
  • Format: PDF

This volume presents an up-to-date compendium of major scientific breakthroughs on human diseases, drug screenings, personalized medicine and regenerative approaches by using stem cells to model or treat the disorders
This book covers what would be the desired strategy for the years to come, by methodically dissecting limitations in our current methodology and understanding of stem cells technology
This book also summarizes state-of-the-art technology (genomics and epigenomics, crispr/cas9, epigenetic tools, bioinformatics approaches, etc) that will push further the applicability and validity of the stem cell application in biomedical research
…mehr

Produktbeschreibung
This volume presents an up-to-date compendium of major scientific breakthroughs on human diseases, drug screenings, personalized medicine and regenerative approaches by using stem cells to model or treat the disorders

This book covers what would be the desired strategy for the years to come, by methodically dissecting limitations in our current methodology and understanding of stem cells technology

This book also summarizes state-of-the-art technology (genomics and epigenomics, crispr/cas9, epigenetic tools, bioinformatics approaches, etc) that will push further the applicability and validity of the stem cell application in biomedical research


Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Autorenporträt
Raul Delgado-Morales holds a PhD in Neuroscience. He completed his doctoral studies at the Universitat Autònoma de Barcelona working in the field of epigenetics as it relates to depression. After that he received a Marie Curie Postdoctoral Fellowship, to continue his research as a postdoc at the Max Planck Institute of Psychiatry in Munich. There he focused on Alzheimer's disease. After four years in Germany, he moved to Bellvitge Biomedical Research Institute (IDIBELL), in Barcelona, to lead research on neuroepigenomics. Currently he is the Scientific Deputy Director of IDIBELL.